Caprock Group LLC Lowers Stake in Accuray Incorporated (NASDAQ:ARAY)

Caprock Group LLC cut its stake in Accuray Incorporated (NASDAQ:ARAY) by 25.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,000 shares of the medical equipment provider’s stock after selling 5,000 shares during the quarter. Caprock Group LLC’s holdings in Accuray were worth $30,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Foundry Partners LLC increased its position in shares of Accuray by 51.3% during the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after purchasing an additional 741,900 shares in the last quarter. State Street Corp grew its holdings in shares of Accuray by 3.8% during the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after buying an additional 70,008 shares during the last quarter. Barclays PLC grew its holdings in shares of Accuray by 97.9% during the third quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock valued at $380,000 after buying an additional 104,310 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Accuray by 1,650.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock valued at $263,000 after acquiring an additional 138,022 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Accuray by 489.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after acquiring an additional 230,695 shares during the last quarter. 64.08% of the stock is owned by institutional investors.

Accuray Stock Down 9.7 %

Accuray stock opened at $2.43 on Friday. Accuray Incorporated has a 52 week low of $1.40 and a 52 week high of $2.95. The firm has a market cap of $244.39 million, a price-to-earnings ratio of -14.29 and a beta of 1.51. The business’s 50-day moving average price is $2.11 and its 200 day moving average price is $1.97. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. As a group, sell-side analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current year.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.